Welcome to the first issue of The Peptide Signal. Each Tuesday, four sections: a landmark study broken down, a protocol examined, a mechanism explained, and the week's regulatory news, without the vendor spin. The intro is free. Full issue is for subscribers.
The biggest obesity drug data drop in years. A mitochondrial peptide gets its first FDA approval. And the most consequential regulatory shift in the peptide compounding space since 2023, with an important caveat that most coverage is missing.
Novo Nordisk's stock dropped 9% the morning of June 22, 2025. The headline from REDEFINE 1: CagriSema produced 20.4% mean body weight reduction at 68 weeks in adults with obesity. That number was below the 25% the market had been expecting, and investors sold.
The same morning, researchers published that result in the New England Journal of Medicine.
Here is what actually happened in that trial, and why the market reaction tells you more about analyst expectations than it does about the compound.
What CagriSema is
CagriSema is a fixed-dose combination of two once-weekly injectable compounds: cagrilintide 2.4 mg (a long-acting amylin analogue) and semaglutide 2.4 mg (the same active ingredient as Wegovy). The two compounds target different but complementary appetite pathways. Semaglutide works primarily through GLP-1 receptor activation in the gut and brain. Cagrilintide works through amylin and calcitonin receptors in the hindbrain and hypothalamus, areas involved in both hunger signaling and satiety. The theoretical basis for combining them is that they hit the same behavioral outcome through independent biological routes.
What REDEFINE 1 actually found
REDEFINE 1 enrolled 3,417 adults without type 2 diabetes who had obesity or overweight with at least one weight-related complication. Participants were randomized in a 21:3:3:7 ratio to CagriSema, semaglutide 2.4 mg alone, cagrilintide 2.4 mg alone, or placebo. All groups received lifestyle intervention. The trial ran 68 weeks.
The results by arm: CagriSema 20.4% mean weight loss (treatment-policy estimand), semaglutide alone 14.9%, cagrilintide alone 11.5%, placebo 3.0%. The combination outperformed either component alone. The difference between CagriSema and semaglutide monotherapy was 5.5 percentage points. 60% of CagriSema participants achieved at least 20% body weight reduction. 23% achieved at least 30%. On the trial-product estimand, the number rises to 22.7%. The combination also improved systolic blood pressure, waist circumference, lipid levels, and glycemic control. In participants with prediabetes, 88% returned to normoglycemia.
The bottom line
CagriSema works. The combination adds meaningful weight loss beyond what either component achieves alone. The 20.4% figure is better than every approved drug on the market, framed against the actual clinical comparison set rather than analyst models. The high GI adverse event rate is the real limitation to watch as more safety data emerges. The market got this one wrong. The biology is intact.
Full premium section: mechanism of dual-pathway satiety suppression, cagrilintide DACRA profile versus pramlintide, REDEFINE 2 diabetes population results (13.7% weight loss), 88% normoglycemia reversal context, and competitive positioning through 2027.
The disappointment in context
The 25% figure that analysts were expecting came from Phase 2 data and early modeling. Phase 2 trials consistently overestimate effect sizes, and this is not specific to CagriSema. The trial used a treatment-policy estimand, which includes participants who discontinued or used rescue therapy, and intentionally produces more conservative figures than the idealized trial-product estimand. This is the methodologically appropriate way to report results for regulatory purposes. It is also consistently lower than what Phase 2 trials report.
20.4% is higher than any approved weight loss drug has achieved in a comparably designed trial. Semaglutide's STEP program, across five major trials, produced 15 to 17% weight loss. Tirzepatide achieved 20 to 21% in the SURMOUNT program. CagriSema at 20.4% lands above semaglutide and approximately level with tirzepatide, and this is the combination's Phase 3 result in a non-diabetic obesity population. The market sold because the number was below an arbitrary expectation. The science shows a drug that outperforms all currently approved alternatives.
What was less good
Gastrointestinal adverse events affected 79.6% of CagriSema participants versus 39.9% in the placebo group. Most were described as transient and mild to moderate. Nausea, vomiting, diarrhea, and constipation followed the pattern typical of GLP-1 therapies but at higher rates than semaglutide monotherapy. This is the expected tradeoff for additional pharmacological activity. Discontinuation data was not separately reported in the topline data available at time of writing. Detailed results are expected at a future medical meeting and in the peer-reviewed publication.
Regulatory status
Novo Nordisk filed a New Drug Application with the FDA in December 2025. FDA review is expected in 2026, with potential approval as early as late 2026 or early 2027. CagriSema is not approved anywhere as of this writing.
The dual-pathway satiety mechanism
The complementary mechanism of CagriSema explains why the combination outperforms either component alone rather than simply adding their effects. GLP-1 receptor agonists like semaglutide act primarily on the vagus nerve and brainstem to reduce gastric emptying and on the arcuate nucleus of the hypothalamus to suppress appetite. The effect is primarily on caloric intake through delayed gastric emptying and centrally mediated satiety signals.
Amylin analogues like cagrilintide act through a different set of receptors: heterodimers of the calcitonin receptor combined with receptor activity modifying proteins (RAMP1, RAMP2, RAMP3) in the area postrema and nucleus of the solitary tract, regions in the hindbrain with incomplete blood-brain barrier coverage. These are distinct from the primary GLP-1 receptor sites. The amylin system particularly affects the hedonic drive to eat (wanting food for reward rather than hunger), which the GLP-1 system addresses less directly. The combination suppresses both homeostatic hunger and hedonic appetite through independent neural pathways.
REDEFINE 2: the diabetes population
The concurrent REDEFINE 2 trial enrolled 1,206 adults with type 2 diabetes and obesity or overweight. CagriSema produced 13.7% mean weight loss at 68 weeks versus 3.4% with placebo, a difference of 10.4 percentage points. 73.5% of CagriSema participants achieved a glycated hemoglobin level of 6.5% or below, compared with 15.9% in the placebo group.
The 13.7% figure in REDEFINE 2 is lower than the 20.4% in REDEFINE 1. This pattern (lower weight loss in diabetic populations) has been consistently observed across GLP-1 therapies and reflects physiological differences in how type 2 diabetes modifies the incretin response. The regulatory significance is that CagriSema demonstrated efficacy in both populations, which will likely support label indications for both obesity and type 2 diabetes.
What 88% normoglycemia reversal means
In REDEFINE 1, 88% of participants with prediabetes returned to normoglycemia at 68 weeks. Prediabetes affects approximately 96 million adults in the United States, roughly 38% of the adult population. Weight loss is the most effective intervention for prediabetes reversal, but sustained weight loss is difficult to achieve without pharmacological support. A drug producing 20.4% weight loss with 88% prediabetes reversal at 68 weeks represents a meaningful clinical intervention for a condition that progresses to type 2 diabetes at a rate of approximately 5 to 10% annually without intervention. Whether this normoglycemia is durable after treatment cessation is the key outstanding question, consistent with data from semaglutide showing weight regain after discontinuation.
Competitive positioning through 2027
The obesity drug competitive landscape through 2027 will be defined by three compounds: semaglutide (approved, dominant market share), tirzepatide (approved, rapidly gaining), and the next-generation candidates. CagriSema (FDA decision expected late 2026 or early 2027) and retatrutide (approval not expected before late 2027) are the two most advanced next-generation candidates. CagriSema at 20.4% positions it above semaglutide but approximately level with tirzepatide's SURMOUNT results. Retatrutide's TRIUMPH-4 result of 28.7% in the osteoarthritis population, if replicated in the pure obesity TRIUMPH-1 and TRIUMPH-2 trials, would place it clearly above all approved competitors. The market is large enough for multiple winners.
Retatrutide and the Knee: What TRIUMPH-4 Actually Tells Us About Who This Drug Is For
This section is available to premium subscribers. Subscribe to access the full newsletter and all premium content.
Elamipretide and Cardiolipin: What the First Mitochondrial Peptide Approval Actually Means
This section is available to premium subscribers. Subscribe to access the full newsletter and all premium content.
The FDA Peptide Reclassification: What Was Announced, What Has Not Changed Yet, and Which Compounds Are Staying Banned
This section is available to premium subscribers. Subscribe to access the full newsletter and all premium content.
For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use